Eli Lilly Sets Up R&D Center In China
This article was originally published in PharmAsia News
Eli Lilly recently set up its China R&D center in Shanghai as a focal point for the company's innovation network. The facility aims to seek, promote and manage collaboration with local companies and academic institutions. Sited at Zhangjiang Hi-Tech Park which houses several of Lilly's current partners, the China team will be responsible for managing outsourced, risk-sharing R&D projects, mutual transfer of candidate drugs and technology, as well as venture capital investment in healthcare across Greater China. The move shows Lilly's stand of deepening investment in China and its growing confidence in local companies' creativity, efficiency and capability in biopharmaceutical research. (Click here for more - Chinese Language)
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.